title: Xeroderma pigmentosum family support group: Helping families and promoting clinical initiatives.
abstract: The past two decades of research into Xeroderma pigmentosum (XP), an autosomal recessive disease, has been marked by significant progress in understanding the molecular basis of this rare disease. More importantly, especially from the perspective of the affected families, is that this knowledge has been applied to diagnose the condition both in utero as well as in the very early days of life. The eight known XP genes and their different phenotypes present a number of challenges that the XP Workshop sponsored by the NIH in 2010 has highlighted. There is little current treatment specifically designed for any of the XP types other than standard dermatological and neurological evaluations and care. The Xeroderma Pigmentosum Family Support Group (XPFSG) is dedicated to serving families with children and adults with all forms of XP and to help them better understand the condition, to identify practical measures which can be taken by the XP patients and their families to mitigate the effects of the disease, and to serve as patient advocates to help families discuss issues with their physicians. We summarize our efforts in terms of outreach within the US and abroad to affected families and discuss XPFSG-sponsored clinical initiatives that include molecular diagnoses, treatment, and initial proof-of-concept studies that can, if successful, improve the lives of XP patients in the near term.
authors.affiliation: XP Family Support Group, Sacramento, CA 95826, USA.
authors.forename: Michele
authors.initials: M
authors.lastname: Milota
authors.forename: Debby Livingstone
authors.initials: DL
authors.lastname: Jones
authors.forename: James
authors.initials: J
authors.lastname: Cleaver
authors.forename: Ijaz S
authors.initials: IS
authors.lastname: Jamall
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D019033:Delivery of Health Care, Integrated / Q000458:organization & administration*; D004224:Diterpenes; D005190:Family; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D035583:Rare Diseases / Q000517:prevention & control / Q000628:therapy; D000084562:Retinyl Esters; D012643:Selenium / Q000627:therapeutic use; D012657:Self-Help Groups / Q000458:organization & administration*; D013473:Sunscreening Agents / Q000009:adverse effects; D014466:Ultraviolet Rays; D014801:Vitamin A / Q000009:adverse effects / Q000031:analogs & derivatives; D014807:Vitamin D / Q000627:therapeutic use; D014983:Xeroderma Pigmentosum / Q000517:prevention & control* / Q000628:therapy; D055815:Young Adult
chemical_list: D004224:Diterpenes; D000084562:Retinyl Esters; D013473:Sunscreening Agents; D014801:Vitamin A; D014807:Vitamin D; C014794:retinol palmitate; D012643:Selenium